Elevated growth differentiating factor 15 expression predicts long‑term benefit of docetaxel, cisplatin and 5‑fluorouracil induction chemotherapy in patients with oral cancer

  • Authors:
    • Xiao Tang
    • Yong‑Jie Hu
    • Wu‑Tong Ju
    • Yong Fu
    • Wen‑Wen Sun
    • Ying Liu
    • Yi‑Ran Tan
    • Li‑Zhen Wang
    • Jiang Li
    • Yao‑Yao Tu
    • Chen‑Ping Zhang
    • Zhi‑Yuan Zhang
    • Lai‑Ping Zhong
  • View Affiliations

  • Published online on: March 22, 2018     https://doi.org/10.3892/ol.2018.8324
  • Pages: 8118-8124
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Our previous phase 3 trial (NCT01542931) failed to demonstrate improved survival when docetaxel, cisplatin and 5‑fluorouracil (TPF) induction chemotherapy was introduced prior to surgery and postoperative radiotherapy in patients with locally advanced oral squamous cell carcinoma (OSCC). The aim of the present study was to investigate the long‑term predictive value of GDF15 expression for potential personalized treatment strategies in OSCC. A total of 256 patients with stage III/IVA OSCC from our phase 3 trial were enrolled in the present study. Immunohistochemical staining against GDF15 was performed in the biopsy samples from 230/256 patients. Kaplan‑Meier analysis, followed by the log‑rank test, and the Cox proportional hazards model were used for outcome analysis using the statistical SPSS 18.0 software package for Windows. Among the 230 patients, low GDF15 expression was detected in 68 patients and high GDF15 expression was detected in 162 patients. With a median follow‑up period of 67 months, the patients with low GDF15 expression exhibited a higher survival rate than those with high GDF15 expression, including 5‑year overall survival (73.4 vs. 57.7%; P=0.059), 5‑year disease‑free survival (64.5 vs. 49.2%; P=0.033), 5‑year locoregional recurrence‑free survival (66.0 vs. 51.5%; P=0.043) and 5‑year distant metastasis‑free survival (73.4 vs. 56.6%; P=0.038) rates. Furthermore, the cT3/4N0M0 patients with high GDF15 expression benefited significantly from TPF induction chemotherapy, including overall survival (HR=0.233; P=0.02), disease‑free survival (HR=0.296; P=0.014), locoregional recurrence‑free survival (HR=0.347; P=0.035) and distant metastasis‑free survival (HR=0.212; P=0.013) rates. The results of the present study suggested that elevated GDF15 expression may be used as a long‑term prognostic biomarker for poor clinical outcomes in patients with locally advanced OSCC. Elevated GDF15 expression in cT3/4N0M0 patients predicts significant long‑term benefit of survival from TPF induction chemotherapy.
View Figures
View References

Related Articles

Journal Cover

May-2018
Volume 15 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tang X, Hu YJ, Ju WT, Fu Y, Sun WW, Liu Y, Tan YR, Wang LZ, Li J, Tu YY, Tu YY, et al: Elevated growth differentiating factor 15 expression predicts long‑term benefit of docetaxel, cisplatin and 5‑fluorouracil induction chemotherapy in patients with oral cancer. Oncol Lett 15: 8118-8124, 2018
APA
Tang, X., Hu, Y., Ju, W., Fu, Y., Sun, W., Liu, Y. ... Zhong, L. (2018). Elevated growth differentiating factor 15 expression predicts long‑term benefit of docetaxel, cisplatin and 5‑fluorouracil induction chemotherapy in patients with oral cancer. Oncology Letters, 15, 8118-8124. https://doi.org/10.3892/ol.2018.8324
MLA
Tang, X., Hu, Y., Ju, W., Fu, Y., Sun, W., Liu, Y., Tan, Y., Wang, L., Li, J., Tu, Y., Zhang, C., Zhang, Z., Zhong, L."Elevated growth differentiating factor 15 expression predicts long‑term benefit of docetaxel, cisplatin and 5‑fluorouracil induction chemotherapy in patients with oral cancer". Oncology Letters 15.5 (2018): 8118-8124.
Chicago
Tang, X., Hu, Y., Ju, W., Fu, Y., Sun, W., Liu, Y., Tan, Y., Wang, L., Li, J., Tu, Y., Zhang, C., Zhang, Z., Zhong, L."Elevated growth differentiating factor 15 expression predicts long‑term benefit of docetaxel, cisplatin and 5‑fluorouracil induction chemotherapy in patients with oral cancer". Oncology Letters 15, no. 5 (2018): 8118-8124. https://doi.org/10.3892/ol.2018.8324